Enliven Therapeutics (ELVN) TD Cowen's 6th Annual Oncology Innovation Summit summary

Company overview and strategic focus

• Focused on precision oncology, specializing in small molecule kinase drug discovery with all assets developed in-house.

• Lead program ELVN-001 targets BCR-ABL for chronic myeloid leukemia (CML), aiming for improved efficacy and tolerability.

• CML treatment goals have evolved toward quality of life and deeper molecular responses, with differentiation in efficacy and tolerability being key.

Clinical data and efficacy highlights

• ELVN-001 phase 1A data showed a 44% cumulative major molecular response (MMR) rate at six months in heavily pretreated CML patients.

• Response achieved rate was 23% (3/13 patients), comparable to Asciminib's 24% in similar settings.

• Recent data cut doubled response-available patients, with efficacy rates holding or improving.

• EHA presentation will include data from about 90 patients, with 50 evaluable for six-month efficacy.

Safety and tolerability profile

• Fewer than 5% dose reductions reported, with no new toxicities and a profile consistent with high ABL1 selectivity.

• Absence of common TKI-related side effects such as gut toxicities and edema; patients remain on drug long-term.

• Safety and tolerability are expected to be key differentiators in the chronic CML setting.